Differential expression of host protein biomarkers among symptomatic clinic attendees finally diagnosed with tuberculosis and other respiratory diseases with or without latent Mycobacterium tuberculosis infection

Namuganga, Anna Ritah; Nsereko, Mary; Bagaya, Bernard Sentalo; Mayanja‐Kizza, Harriet; Chegou, Novel N.

doi:10.1016/j.imlet.2022.11.006

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study used healthy controls and the cut-off value was chosen to reach the highest diagnostic accuracy for their cohort. In studies with a mix of HIV-positive and -negative adults, three individual biomarkers, CRP (30), IP-10 (31), and NCAM (32) met the TPP criteria in at least two of the studies. As these studies all used patients with symptoms of presumed TB as the comparator, the risk of bias was low.…”

Section: Resultsmentioning

confidence: 99%

“…When considering the risk of bias, the most promising individual host proteins for adult PTB are CRP (30), IP-10 (31), NCAM-1 (32), and SAA (48). These markers not only met TPP criteria but were evaluated in clinically relevant populations of patients with presumptive TB symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…CD14 was the best performing marker out of the limited number tested in PLHIV (29), and also performed well in HIV-negative participants (22). In studies evaluating participants with ORD that enrolled a population of mixed HIV status, CRP (32) and IP-10 (31) had high accuracy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Host blood protein biomarkers to screen for Tuberculosis disease: a systematic review and meta-analysis

Gaeddert,

Glaser,

Chendi

et al. 2024

Preprint

View full text Add to dashboard Cite

IntroductionNon-sputum tests are needed to improve TB diagnosis and close the diagnostic gap. The World Health Organization target product profile (TPP) for point-of-care (POC) screening tests requires minimum sensitivity 90% and specificity 70%. Our objective was to identify host blood protein biomarkers meeting TPP criteria.MethodsA systematic review was conducted and reported following PRISMA guidelines. Data extraction and quality assessment with QUADAS-2 were completed for included studies. Heterogeneity was assessed. For biomarkers reporting sensitivity and specificity in at least four studies, a random-effects meta-analysis was performed for biomarkers with similar cut-offs.ResultsWe screened 4,651 citations and included 65 studies that enrolled 16,010 participants and evaluated 156 host proteins. Most (47/65) studies enrolled adult pulmonary TB (PTB), with 15 studies in adult extra-pulmonary TB and 5 in children. Small early-stage discovery studies with case-control design were common (24/65) and had high risk of bias. For adult PTB, CRP, IP-10, NCAM-1, and SAA met TPP criteria in high-quality studies. There was a high degree of heterogeneity in biomarker cut-offs and study design. CRP at 10mg/L cut-off was meta-analyzed from 10 studies; pooled sensitivity 86% (95% CI: 80-95) and pooled specificity 67% (95% CI: 54-79). In people living with HIV (6 studies) CRP pooled sensitivity was 93% (95% CI: 90-95) and pooled specificity 59% (95% CI: 40-78).DiscussionWe identified promising biomarkers that performed well in high-quality studies. Data overall are limited and highly heterogenous. Further standardized validation across subgroups in prospective studies is needed before translating into POC assays.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Host blood protein biomarkers to screen for Tuberculosis disease: a systematic review and meta-analysis

Gaeddert,

Glaser,

Chendi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…We further discuss different sample types, experimental platforms, and briefly the signaling pathways associated with the identified host-derived proteins. [12,13], [17], [29], [63] # , [66], [103][104][105][106][107][108][109][110][111][112][113][114] Mass spectrometry [22][23][24], [25] # , [115][116][117][118][119][120][121][122][123][124][125][126][127]] SOMAscan [19,20] Other [21], [70], [78], [128,129] Sputum/Saliva ELISA [7] Multiplex bead assay [14], [29] Mass spectrometry [26], [30], [31] # , [32]<...…”

Section: Introductionmentioning

confidence: 99%

From simple to complex: Protein‐based biomarker discovery in tuberculosis

Mousavian,

Källenius,

Sundling

2023

Eur J Immunol

View full text Add to dashboard Cite

Tuberculosis (TB) is a deadly infectious disease that affects millions of people globally. TB proteomics signature discovery has been a rapidly growing area of research that aims to identify protein biomarkers for the early detection, diagnosis, and treatment monitoring of TB. In this review, we have highlighted recent advances in this field and how it is moving from the study of single proteins to high‐throughput profiling and from only using proteomics to include additional types of data in multi‐omics studies. We have further covered the different sample types and experimental technologies used in TB proteomics signature discovery, focusing on studies of HIV‐negative adults. The published signatures were defined as either coming from hypothesis‐based protein targeting or from unbiased discovery approaches. The methodological approaches influenced the type of proteins identified and were associated with the circulating protein abundance. However, both approaches largely identified proteins involved in similar biological pathways, including acute‐phase responses and T‐helper type 1 and type 17 responses. By analysing the frequency of proteins in the different signatures, we could also highlight potential robust biomarker candidates. Finally, we discuss the potential value of integration of multi‐omics data and the importance of control cohorts and signature validation.This article is protected by copyright. All rights reserved

show abstract

The Integration of Omics: A Promising Approach to Personalized Tuberculosis Treatment

Guha,

Dutta,

Murti

et al. 2024

Medicine in Omics

View full text Add to dashboard Cite

Differential expression of host protein biomarkers among symptomatic clinic attendees finally diagnosed with tuberculosis and other respiratory diseases with or without latent Mycobacterium tuberculosis infection

Cited by 3 publications

References 29 publications

Host blood protein biomarkers to screen for Tuberculosis disease: a systematic review and meta-analysis

Host blood protein biomarkers to screen for Tuberculosis disease: a systematic review and meta-analysis

From simple to complex: Protein‐based biomarker discovery in tuberculosis

The Integration of Omics: A Promising Approach to Personalized Tuberculosis Treatment

Contact Info

Product

Resources

About